Ole-Erik Iversen

Guest Researcher

Department of Clinical Science

E-mailole-erik.iversen@uib.no
Visitor Address
Haukeland universitetssykehus, Laboratoriebygget

5009 Bergen
Postal Address
Postboks 7804

5020 Bergen

Publications

Academic article

Show author(s) (2022). Randomized implementation of a primary human papillomavirus testing-based cervical cancer screening protocol for women 34 to 69 years in Norway. Cancer Epidemiology, Biomarkers and Prevention. 1812-1822.

Show author(s) (2019). Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology. 110-117.

Show author(s) (2018). Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Human Vaccines & Immunotherapeutics. 396-403.
Show author(s) (2018). Medikamentell abort hos avtalespesialist. Tidsskrift for Den norske legeforening. 823-828.
Show author(s) (2018). Human papillomavirus type specific risk of progression and remission during long-term follow-up of equivocal and low-grade HPV-positive cervical smears. International Journal of Cancer. 851-860.

Show author(s) (2017). Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy. Acta Obstetricia et Gynecologica Scandinavica. 547-555.
Show author(s) (2017). Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - a combined analysis of five phase III clinical trials. Papillomavirus Research. The Journal of HPV and other Small DNA Tumor Viruses. 105-115.
Show author(s) (2017). Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16?26 years: a randomised, double-blind trial. The Lancet. 2143-2159.
Show author(s) (2017). 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics.

Show author(s) (2016). Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics.
Show author(s) (2016). Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
Show author(s) (2016). Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. Journal of the American Medical Association (JAMA). 2411-2421.
Show author(s) (2016). Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Research. The Journal of HPV and other Small DNA Tumor Viruses. 61-69.

Show author(s) (2015). Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia. Expert Opinion on Investigational Drugs. 273-281.
Show author(s) (2015). Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Human Vaccines & Immunotherapeutics. 1313-1322.
Show author(s) (2015). A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. American Journal of Obstetrics and Gynecology. 465.e1-465.e7.
Show author(s) (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine. 711-723.

Show author(s) (2014). Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway. Gynecologic Oncology. 159-166.
Show author(s) (2014). Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation. Acta Obstetricia et Gynecologica Scandinavica. 647-653.
Show author(s) (2014). Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. e657-e665.
Show author(s) (2014). Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiology, Biomarkers and Prevention. 1997-2008.

Show author(s) (2012). Er det mulig å få pålitelig kunnskap om psykiske senvirkninger etter provosert abort? Tidsskrift for Den norske legeforening. 1450-1452.

Show author(s) (2011). Decline of arterial cerebral infarction among young women: the Bergen Stroke Study. Vascular Health and Risk Management. 81-84.
Show author(s) (2011). Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. International Journal of Cancer. 1344-1353.

Show author(s) (2010). Oral Contraceptives and Venous Thromboembolism Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009. Journal of family planning and reproductive health care. 117-122.
Show author(s) (2010). Medical Abortion at 63 to 90 Days of Gestation. Obstetrics and Gynecology. 962-968.
Show author(s) (2010). Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on all HPV-associated genital diseases in young women. Journal of the National Cancer Institute. 325-339.
Show author(s) (2010). Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. British Medical Journal. 9 pages.

Show author(s) (2009). Wrapping of the legs versus phenylephrine for reducing hypotension in parturients having epidural anaesthesia for caesarean section: a prospective, randomized and double-blind study. European Journal of Anaesthesiology. 842-846.
Show author(s) (2009). The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. Journal of the European Academy of Dermatology and Venereology. 1147-1155.
Show author(s) (2009). The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. Journal of Infectious Diseases. 936-944.
Show author(s) (2009). The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. Journal of Infectious Diseases. 926-935.
Show author(s) (2009). Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines. 696-704.
Show author(s) (2009). Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
Show author(s) (2009). A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prevention Research. 868-878.

Show author(s) (2008). Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ. British Medical Journal. 5 pages.
Show author(s) (2008). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Journal of the National Cancer Institute. 475-482.
Show author(s) (2008). HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 6844-6851.

Show author(s) (2007). Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases. 1438-1446.
Show author(s) (2007). Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 4931 -4939.
Show author(s) (2007). Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. Acta Obstetricia et Gynecologica Scandinavica. 1490-1495.
Show author(s) (2007). Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet. 1861-1868.

Show author(s) (2006). NorChip saken - nok en gang. Gynekologen. 18-21.
Show author(s) (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer. 1459-1466.

Show author(s) (2005). Molekylærdiagnostiske metoder innen gynekologisk kreft. Tidsskrift for Den norske legeforening. 3120-3123.
Show author(s) (2005). Har conisering betydning for svangerskapsutfall? Gynekologen. 45-46.
Show author(s) (2005). Ascitic complement system in ovarian cancer. British Journal of Cancer. 895-905.
Show author(s) (2005). A significant change in Norwegian gynecologist´s attitude to hormone therapy is observed after the results of the Women´s Health Initiative Study. Acta Obstetricia et Gynecologica Scandinavica. 92-93.
Show author(s) (2005). A significant change in Norwegian gynecologists attitude to hormone replacement therapy is observed after the results of the Women's health initiative study. Acta Obstetricia et Gynecologica Scandinavica. 92-93.

Show author(s) (2004). Tredjegenerasjons p-piller - hvor stor er risikoen for venøs tromboemboli? Tidsskrift for Den norske legeforening. 1521-1522.
Show author(s) (2004). Screening for serum total homocysteine in newborn children. Clinical Chemistry. 1769-1784.
Show author(s) (2004). Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric. 210-216.
Show author(s) (2004). Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
Show author(s) (2004). HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. The Lancet. 453-455.

Show author(s) (2001). The development of high venous velocity of the fetal umbilical ring during gestational weeks 11–19. British Journal of Obstetrics and Gynaecology. 248-253.
Show author(s) (2001). Mifepristone (RU 486) - et kontroversielt legemiddel med stort potensiale. Tidsskrift for Den norske legeforening. 3286-3289.
Show author(s) (2001). Mifepriston - et kontroversielt legemiddel med stort potensiale. Tidsskrift for Den norske legeforening. 3658.
Show author(s) (2001). Knowledge, attitudes and management strategies in Scandinavia concerning hormone replacement thereapy. A comparison between gynecologists in Denmark, Norway and Sweden. Maturitas. 83-90.
Show author(s) (2001). Knowledge, attitudes and management strategies in Scandinavia concerning Hormone replacement therapy. Maturitas. 83-90.
Show author(s) (2001). Gestagentillegg ved østrogenbehandling i klimakteriet. Tidsskrift for Den norske legeforening. 82-83.
Show author(s) (2001). Early pregnancy termination with mifepristone and misiprostol in Norway. Acta Obstetricia et Gynecologica Scandinavica. 1056-1061.
Show author(s) (2001). Beliefs about the use of oral contraception among women in Oslo, Norway. Scandinavian Journal of Sexology. 3-24.

Show author(s) (2000). The effects of progestogens on the endometrium. Workshop (Sverige. Läkemedelsverket).
Show author(s) (2000). Rehabilitering av kvinner med brystkreft. Tidsskrift for Den norske legeforening. 2749-2754.
Show author(s) (2000). Methylation of hMLH1 in a population-based series of endometrial carcinoma. Clinical Cancer Research. 3607-3613.
Show author(s) (2000). Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene. Clinical Cancer Research. 4026-4032.
Show author(s) (2000). Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Research. 1750-1752.

Show author(s) (1999). Retained placenta: incidence and clinical significance. Acta Obstetricia et Gynecologica Scandinavica. 33-36.
Show author(s) (1999). Prognostic significance of tumor angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. Journal of Clinical Oncology. 1382-1390.
Show author(s) (1999). Prognostic significance of angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. International Journal of Oncology. 395-399.
Show author(s) (1999). Consensus conference statement on combination oral contraceptives and cardiovascular disease. Fertility and Sterility. 1S-6S.

Show author(s) (1998). Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer. 956-964.
Show author(s) (1998). Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
Show author(s) (1998). Poorer survival of nulliparous women with endometrial carcinoma. Cancer. 1328-1333.
Show author(s) (1998). Norske gynekologers holdning til østrogen substitusjon. Tidsskrift for Den norske legeforening. 2944-2946.
Show author(s) (1998). Norske gynekologers holdning til og praksis ved hormonsubstitusjonsbehandling i klimakteriet. Tidsskrift for Den norske legeforening. 2940-2943.
Show author(s) (1998). Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
Show author(s) (1998). Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
Show author(s) (1998). Identification of high-risk patients by assessment of nuclear Ki67 expression in a prosepective study of endometrial carcinoma patients. Clinical Cancer Research. 2779-2785.
Show author(s) (1998). Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clinical Cancer Research. 2779-2785.
Show author(s) (1998). Decreased survival for nulliparous women with endometrial carcinoma. Is the relationship due to biology or behaviour? Cancer. 1328-1333.
Show author(s) (1998). Bør antiprogesteron tas i bruk ved svangerskapsavbrudd? Tidsskrift for Den norske legeforening. 12.
Show author(s) (1998). Bør antiprogesteron tas i bruk i Norge? Tidsskrift for Den norske legeforening. 212-213.

Show author(s) (1997). Vurdering av trombosetendens før forskrivning av p-piller. Tidsskrift for Den norske legeforening. 281-282.
Show author(s) (1997). Tromboembolisk sykdom i graviditet og barseltid, underliggende trombofili? Gynekologen. 45.
Show author(s) (1997). Svangerskapsavbrudd ved gruppe 1 sykehus i 1996. Tidsskrift for Den norske legeforening. 558.
Show author(s) (1997). Recurrent endometrial carcinoma and the value of routine follow-up. British Journal of Obstetrics and Gynaecology. 1302-1307.
Show author(s) (1997). Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
Show author(s) (1997). Prognostisk betydning av tumorbiologiske markører ved kreft i livmorslimhinnen. Kreftnytt. 4-7.
Show author(s) (1997). Norske gynekologers innstilling til hormonell substitusjon. Gynekologen. 51-52.
Show author(s) (1997). Cell division in placentas of appropriate and small-for-gestational-age infants. A flow cytometry study. Acta Obstetricia et Gynecologica Scandinavica. 59-62.
Show author(s) (1997). Cell division in placentas of appropriate and small for gestational age infants. Acta Obstetricia et Gynecologica Scandinavica. 59-62.
Show author(s) (1997). Cell division in placentas of appropriate and small for gestational age infants. Acta Obstetricia et Gynecologica Scandinavica. 59-62.

Academic lecture

Show author(s) (2011). MEDICAL ABORTION WITH HOME ADMINISTRATION OF MISOPROSTOL UP TO 63 DAYS GESTATION.

Show author(s) (2005). A burden of global proportions.

Show author(s) (2004). Hvordan forholder vi oss i dag til brystkreftpasienter og risikokvinner mht østrogenbehandling?
Show author(s) (2004). Human papilloma vaccines.
Show author(s) (2004). Hormonbehandling etter brystkreft. Status i HABITS studien.
Show author(s) (2004). HRT til kvinner med cancer.
Show author(s) (2004). HABITS studien. Hvordan forholder vi oss i dag til brystkreftpasienter og risikokvinner mht østrogenbehandling?
Show author(s) (2004). Corpuscancer.
Show author(s) (2004). Changes in attitudes and use of hormone replacement therapy among Scandinavian Gynecologists.
Show author(s) (2004). Breast issues with hormone therapy.

Show author(s) (2003). Østrogenbehandling. Er det blitt farligere? Hvilke indikasjoner gjelder? Kontraindikasjoner?
Show author(s) (2003). Østrogenbehandling for klimakterielt besvær - er det trygt etter brystkreft?
Show author(s) (2003). Østrogenbehandling.
Show author(s) (2003). a)HRT og CVD, b)HRT og cancer.
Show author(s) (2003). Sikkerhetsaspekter, brystkreft og andre kreftformer, økning/reduksjon ved HRT.
Show author(s) (2003). SMM rapport ovarialcancer og "HRT etter ca. mammae - er det trygt?".
Show author(s) (2003). Postoperativ kjemoterapi ved ovarialcancer.
Show author(s) (2003). P-piller-trombose.
Show author(s) (2003). P-piller.
Show author(s) (2003). Hjerte/karsykdom og østrogenbehandling.
Show author(s) (2003). HRT og cancer.
Show author(s) (2003). HRT og cancer.
Show author(s) (2003). HRT og cancer.
Show author(s) (2003). HRT og cancer.
Show author(s) (2003). HRT og cancer.
Show author(s) (2003). HRT og cancer.
Show author(s) (2003). HRT og cancer.
Show author(s) (2003). HRT etter cancer mammae - er det trygt?
Show author(s) (2003). HRT etter HERS og WHI. Veien videre (Jordskjelv eller krusninger??).
Show author(s) (2003). HRT eller WHI??
Show author(s) (2003). HRT eller WHI??
Show author(s) (2003). HRT and breast cancer. Hot topics in Gyn/Obst.
Show author(s) (2003). HPV-vaksine. Kan cervixcancer forebygges?
Show author(s) (2003). HPV-vaksinasjon. Bakgrunn og strategi.
Show author(s) (2003). Global gene expression profiling of human cancers using DNA microarray technology - examples, pitfalls and outlook.
Show author(s) (2003). Cx cancer: Fra naturlig forløp via terapi, sekundær -, til primærprofylakse.
Show author(s) (2003). Corpuscancer.
Show author(s) (2003). Bruk og misbruk av epidemiologiske data.
Show author(s) (2003). Blødningsforstyrrelser.
Show author(s) (2003). A change in attitudes and prescribing practice of hormone replacement therapy among Norwegian gynaecologists during the last 5 years.

Show author(s) (2001). Substitusjonsbehandling i klimakteriet.
Show author(s) (2001). Oppdatering prevensjon, p-piller og hormonelle metoder. Abortmetoder.
Show author(s) (2001). Medisinsk abort - hvorfor og hvordan?
Show author(s) (2001). HRT og coloncancer - er der en sammenheng?
Show author(s) (2001). HRT og cancer mammae. HABITS-studien status 2001.
Show author(s) (2001). HRT og cancer hos postmenopausale kvinner. En oppdatering.
Show author(s) (2001). HRT cancer.
Show author(s) (2001). HABITS-studien. Bakgrunn og status.
Show author(s) (2001). HABITS-studien. Bakgrunn og status.
Show author(s) (2001). HABITS-studien (Hormonal Replacement Therapy After Breast Cancer diagnosis - is it safe?). Bakgrunn og status.
Show author(s) (2001). HABITS studien (Hormonal replacement therapy after breast cancer diagnosis - is it safe?) Bakgrunn og status.
Show author(s) (2001). Corpuscancer.
Show author(s) (2001). Bruk og misbruk av epidemiologiske data ved HRT og cancer mammae.
Show author(s) (2001). Blødningsforstyrrelser i klimakteriet.

Show author(s) (2000). Østrogenbehandling og kreftrisiko.
Show author(s) (2000). The endometrium in postmenopausal asymptomatic women. Findings with transvaginal ultrasonography (TVS) and clinical relevance.
Show author(s) (2000). Surgical evaluation following medically induced second trimester abortion. A Nordic Investigation.
Show author(s) (2000). Surgical evacuation following medically induced second trimester abortion.
Show author(s) (2000). Substitusjonsbehandling i klimakteriet.
Show author(s) (2000). Medisinsk abort - hvorfor og hvordan?
Show author(s) (2000). Hormonsubstitusjon og kreftrisiko.
Show author(s) (2000). HTR og mammacancer, HABITS studien.
Show author(s) (2000). HRT og brystcancer, relasjon til osteporose profylakse, fremtidige perspektiver.
Show author(s) (2000). HRT i går, i dag og i morgen.
Show author(s) (2000). HRT before, today and in the future.
Show author(s) (2000). Gynekologiske cancere og HRT.
Show author(s) (2000). Corpuscancer.
Show author(s) (2000). Cancer mammae og HRT.
Show author(s) (2000). Blødningsforstyrrelser i Klimakteriet.

Show author(s) (1997). Use of the Janus serum bank in cancer research.
Show author(s) (1997). Standardisert registrering av behandling av premaligne lidelser i cervix uteri, et prøveprosjekt i Helseregion III og IV.
Show author(s) (1997). Peripartum hysterektomi - Insidens og maternell morbiditet.
Show author(s) (1997). Peripartum hysterectomy. Incidence and maternal morbidity.
Show author(s) (1997). Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].